Loading company
Nurix Therapeutics, Inc.
NRIX · Nasdaq · ·
Next earnings: October 8, 2026
$23.69+0.1%Sep 29 close
- 1M
- -9.6%
- 6M
- +61.5%
- 1Y
- +156.4%
- 5Y
- -30.9%
NRIX · Nasdaq · ·
Next earnings: October 8, 2026
$23.69+0.1%Sep 29 close
Nurix Therapeutics, Inc. is scheduled to report next on October 8, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending May 31, 2026, against the same quarter a year earlier.
| Measure | 3 months toMay 31, 2026 | 3 months toMay 31, 2025 | Change |
|---|---|---|---|
| Total Revenue | $9M | $44.1M | -79.47% |
| Profit | -$89.5M | -$43.5M | -106.00% |
| Profit per share | -$0.81 | -$0.52 | -55.77% |
| Free Cash Flow | -$98.5M | -$65.8M | -49.63% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“The second quarter of 2026 was a defining period for Nurix and the targeted protein degradation field,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Bexobrutideg (NX-5948) is an investigational, orally bioavailable, brain-penetrant, highly selective small-molecule degrader of Bruton’s tyrosine kinase (BTK) being developed by Nurix and Roche as a potential best-in-class therapy across oncology, immunology and neurology. Bexobrutideg is currently being evaluated in the DAYBreak CLL-201 clinical trial (NCT07221500), a pivotal single-arm Phase 2 study in patients with relapsed or refractory chronic lymphocytic leukemia (CLL), and in the NX-5948-301 Phase 1a/1b clinical trial (NCT05131022) in patients with relapsed or refractory B-cell malignancies. A new tablet formulation of bexobrutideg is also being evaluated in a first-in-human single-ascending-dose and multiple-ascending-dose study in healthy volunteers (NCT06717269) to support future development in immunology and neurology indications. Additional information about ongoing clinical trials can be found at clinicaltrials.gov.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Nurix Therapeutics, Inc.’s Item 2.02 8-K filed July 9, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Nurix Therapeutics, Inc. has no earnings call transcript available.